Published in Eur J Neurosci on February 01, 1998
Neurophysiology and neuroanatomy of reflexive and volitional saccades: evidence from studies of humans. Brain Cogn (2008) 1.71
Interaction between amount and pattern of training in the induction of intermediate- and long-term memory for sensitization in aplysia. Learn Mem (2002) 1.40
Spike-based population coding and working memory. PLoS Comput Biol (2011) 1.23
Contextual modulation of memory consolidation. Learn Mem (2000) 1.09
Linking microcircuit dysfunction to cognitive impairment: effects of disinhibition associated with schizophrenia in a cortical working memory model. Cereb Cortex (2012) 1.09
Short-Term Facilitation may Stabilize Parametric Working Memory Trace. Front Comput Neurosci (2011) 1.08
Homologous mechanisms of visuospatial working memory maintenance in macaque and human: properties and sources. J Neurosci (2012) 0.99
The temporal dynamics of retention of a context memory: something is missing. Learn Mem (2005) 0.92
Integration of target and hand position signals in the posterior parietal cortex: effects of workspace and hand vision. J Neurophysiol (2012) 0.91
Influence of age, spatial memory, and ocular fixation on localization of auditory, visual, and bimodal targets by human subjects. Exp Brain Res (2012) 0.87
Memory-guided saccades in Parkinson's disease: long delays can improve performance. Exp Brain Res (2005) 0.81
Neural correlates of stimulus reportability. J Cogn Neurosci (2009) 0.80
Interareal coupling reduces encoding variability in multi-area models of spatial working memory. Front Comput Neurosci (2013) 0.79
Acquisition vs. memorization trade-offs are modulated by walking distance and pattern complexity in a large-scale copying paradigm. PLoS One (2011) 0.77
Encoding certainty in bump attractors. J Comput Neurosci (2013) 0.76
Modality dependence and intermodal transfer in the Corsi Spatial Sequence Task: Screen vs. Floor. Exp Brain Res (2016) 0.75
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain (1999) 2.00
Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci U S A (1997) 1.99
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology (1998) 1.96
Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem (1992) 1.91
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Relation of anosognosia to frontal lobe dysfunction in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1994) 1.85
Parkinson's disease and sleepiness: an integral part of PD. Neurology (2002) 1.85
Eye movements in parkinsonian syndromes. Ann Neurol (1994) 1.84
Cortical control of reflexive visually-guided saccades. Brain (1991) 1.84
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol (1996) 1.77
A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology (2008) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology (1987) 1.70
Pallidal stimulation for Parkinson's disease. Two targets? Neurology (1997) 1.69
Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res (1983) 1.67
Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum Mol Genet (1998) 1.64
Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry (2005) 1.60
Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. Genomics (1989) 1.59
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol (1978) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci (1999) 1.58
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol (1999) 1.57
Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet (1998) 1.56
Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD. Neurology (2000) 1.55
Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. Hum Mol Genet (1994) 1.49
Absence of linkage to 8q24 in a European family with familial adult myoclonic epilepsy (FAME). Neurology (2002) 1.48
Decisional role of the dorsolateral prefrontal cortex in ocular motor behaviour. Brain (2003) 1.47
Neural substrate of antisaccades: role of subcortical structures. Neurology (2004) 1.46
Ropinirole without levodopa in Parkinson's disease. Lancet (1990) 1.46
Role of pontine nuclei damage in smooth pursuit impairment of progressive supranuclear palsy: a clinical-pathologic study. Neurology (1994) 1.46
Delayed response tasks and prefrontal lesions in man--evidence for self generated patterns of behaviour with poor environmental modulation. Neuropsychologia (1993) 1.45
Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler (2007) 1.45
Influence of visual information on cerebellar saccadic dysmetria. Ann Neurol (1994) 1.44
[The L-dopa test in Parkinson's disease]. Rev Neurol (Paris) (1985) 1.42
Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Ann Neurol (1999) 1.40
Cortical control of saccades. Ann Neurol (1995) 1.40
Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res (1982) 1.40
Clinical characteristics and topography of lesions in movement disorders due to thalamic lesions. Neurology (2001) 1.39
Progressive necrosis of the conus medullaris: magnetic resonance imaging and surgical findings. Neurosurgery (1990) 1.39
[Dystonia, tremor and repetitive instrumental use]. Rev Neurol (Paris) (2008) 1.39
[Post-lumbar puncture syndrome. Causes, prevention, treatments]. Rev Neurol (Paris) (1997) 1.39
Levodopa: why the controversy? Lancet (2002) 1.39
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
Memory disorders in probable Alzheimer's disease: the role of hippocampal atrophy as shown with MRI. J Neurol Neurosurg Psychiatry (1995) 1.38
Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain (2002) 1.38
Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? Brain (2000) 1.36
Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease. Neurology (1986) 1.35
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32
The 'one-and-a-half' syndrome. Electro-oculographic analyses of five cases with deductions about the Physiological mechanisms of lateral gaze. Brain (1981) 1.32
Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology (1980) 1.32
Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord (1994) 1.32
Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci (2001) 1.31
Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry (2005) 1.31
Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol (1993) 1.31
Congruent unilateral impairments for real and imagined hand movements. Neuroreport (1995) 1.30
Eye movement disorders after frontal eye field lesions in humans. Exp Brain Res (1994) 1.30